Letter: Generalized skin drug eruption to natalizumab in a patient with multiple sclerosis

Dermatology Online Journal

Volumn 16, Issue 6, 2010, Pages

  André, Marisa C ^a   Pacheco, David ^a   Antunes, Joana ^a   Silva, Raquel ^a   Filipe, Paulo ^a   de Almeida, L M Soares ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALFUZOSIN; AMITRIPTYLINE; ASPARTATE AMINOTRANSFERASE; BETA1 INTERFERON; CARBAMAZEPINE; CLORAZEPATE DIPOTASSIUM; GAMMA GLUTAMYLTRANSFERASE; GLATIRAMER; LACTATE DEHYDROGENASE; MEXAZOLAM; NATALIZUMAB;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; CASE REPORT; DRUG ERUPTION; ECHOGRAPHY; EDEMA; EOSINOPHILIA; ERYTHEMA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; MALE; MULTIPLE SCLEROSIS; NAUSEA; RARE DISEASE; SKIN DEFECT; SKIN MANIFESTATION; SKIN PRURITUS; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 77958143020     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Letter

References (1)

1. Miller D., M.D., Omar A. Khan, M.D. et al, for the International Natalizumab Multiple Sclerosis Trial Group. A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. 2003. N Engl J Med. 348; 1: 15-23. [PubMed]